Regorafenib | BAY 73-4506;Fluoro-Sorafenib;Regorafenib. trade name: Stivarga. | 瑞格非尼 | Tyrosine / EGF Receptor Protein Kinase Inhibitor | c-RET | VEGFR | Apoptosis

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	c-RET ↓ ↑	其他靶点	纯度
Regorafenib	+++ RET, IC50: 1.5 nM		98%
TG101209	++ RET, IC50: 17 nM	FLT3	99%+
Danusertib	+ RET, IC50: 31 nM		99%+
AD80	++++ RET wt, IC50: 1.3 nM RET V804M, IC50: 0.6 nM	Raf,Src	99+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2/Flk1, IC50: 3 nM VEGFR2, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	c-Kit,FGFR,PDGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Fms/CSF1R,c-Kit	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ hVEGFR2, IC50: 9 nM mVEGF2, IC50: 165 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2/Flk1, IC50: 90 nM VEGFR2, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	FLT3,RET	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cell Line SKMEL239 Parental (PAR) cells C3 cells PC9 cells HCT116 cells HCT116 cells Hep3B PLC/PRF/5 HepG2 RIL-175 cells HCA1 cells T24R1 cells T24R2 cells	Concentration	Treated Time	Description	References
SKMEL239 Parental (PAR) cells	2 μM	1 h	inhibit MAPK signaling	Cancer Discov. 2021 Jul;11(7):1716-1735.
C3 cells	2 μM	1 h	inhibit MAPK signaling	Cancer Discov. 2021 Jul;11(7):1716-1735.
PC9 cells	2 μM	1 h	inhibit MAPK signaling	Cancer Discov. 2021 Jul;11(7):1716-1735.
HCT116 cells	40 µM	48 h	Analysis of Regorafenib-induced apoptosis showed that FBW7 wild-type cells were more prone to apoptosis compared to FBW7 mutant cells.	Oncogene. 2017 Feb 9;36(6):787-796.
HCT116 cells	5 µM		Analysis of the effect of Regorafenib on Mcl-1 protein levels showed that Mcl-1 was significantly reduced in FBW7 wild-type cells but not in FBW7 mutant cells.	Oncogene. 2017 Feb 9;36(6):787-796.
Hep3B	1 μM, 2.5 μM, 5 μM, 7.5 μM, 10 μM	72 or 96 h	Regorafenib inhibited the growth of Hep3B cells in a concentration- and time-dependent manner, with an IC50 of 5 μM.	J Cell Physiol. 2013 Feb;228(2):292-7.
PLC/PRF/5	1 μM, 2.5 μM, 5 μM, 7.5 μM, 10 μM	72 or 96 h	PLC/PRF/5 cells responded similarly to Hep3B cells.	J Cell Physiol. 2013 Feb;228(2):292-7.
HepG2	1 μM, 2.5 μM, 5 μM, 7.5 μM, 10 μM	72 or 96 h	HepG2 cells were more sensitive to Regorafenib, with an approximate IC50 of 1 μM.	J Cell Physiol. 2013 Feb;228(2):292-7.
RIL-175 cells	1 µM	36 h	To study the effect of Regorafenib on CXCL10 secretion by RIL-175 cells, results showed that Regorafenib significantly increased CXCL10 secretion	J Immunother Cancer. 2020 Nov;8(2):e001435.
HCA1 cells	1 µM	36 h	To study the effect of Regorafenib on CXCL10 secretion by HCA1 cells, results showed that Regorafenib increased CXCL10 secretion to a lesser extent	J Immunother Cancer. 2020 Nov;8(2):e001435.
T24R1 cells	1, 6.25, 12.5, 25, 50 µM	12, 24, 48 h	Regorafenib significantly decreased the viability of T24R1 cells and inhibited the expression of stemness and EMT markers.	Int J Mol Sci. 2023 Dec 18;24(24):17610.
T24R2 cells	1, 6.25, 12.5, 25, 50 µM	12, 24, 48 h	Regorafenib significantly decreased the viability of T24R2 cells and inhibited the expression of stemness and EMT markers.	Int J Mol Sci. 2023 Dec 18;24(24):17610.

Species Mice Nude mice Mice Nude mice Nude mice Mice	Animal Model Acute myeloid leukemia (AML) model HCT116 xenograft model HCC model with liver damage T24R1 and T24R2 xenograft tumor model BRAF(V600E) CRC tumor models HT-29 and HCT116 human colorectal cancer xenograft models	Administration	Dosage	Frequency	Description	References
Mice	Acute myeloid leukemia (AML) model	Oral	5 mg/kg	Once daily for 1 month	To evaluate the therapeutic potential of Regorafenib in the AML model, results showed that AML cells in the periphery and spleen were sensitive to treatment, while those in the bone marrow were protected.	J Hematol Oncol. 2017 Oct 6;10(1):162
Nude mice	HCT116 xenograft model	Oral	30 mg/kg	10 consecutive days	Evaluation of the antitumor effects of Regorafenib in vivo showed that FBW7 wild-type tumors were more sensitive to Regorafenib, while Mcl-1 degradation was blocked and apoptosis was reduced in FBW7 knockout tumors.	Oncogene. 2017 Feb 9;36(6):787-796.
Mice	HCC model with liver damage	Oral	5, 10, 20 mg/kg	Once daily for 5 days	To study the effect of Regorafenib combined with PD1 blockade on vascular structure and function, antitumor immunity, tumor growth, and survival in HCC mouse models, results showed that 10 mg/kg Regorafenib combined with PD1 blockade significantly improved survival	J Immunother Cancer. 2020 Nov;8(2):e001435.
Nude mice	T24R1 and T24R2 xenograft tumor model	Intraperitoneal injection	20 mg/kg	20 consecutive days	Regorafenib significantly inhibited the growth of T24R1 and T24R2 xenograft tumors, reduced tumor proliferation and angiogenesis, and promoted tumor cell apoptosis.	Int J Mol Sci. 2023 Dec 18;24(24):17610.
Nude mice	BRAF(V600E) CRC tumor models	Oral	30 mg/kg	Once daily for 40 or 60 days	Suppress tumor growth	Cancer Discov. 2021 Jul;11(7):1716-1735.
Mice	HT-29 and HCT116 human colorectal cancer xenograft models	Oral	30 mg/kg	Once daily for 7 days	To investigate the mechanisms of tumor revascularization after regorafenib withdrawal	J Extracell Vesicles. 2021 May;10(7):e12096

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02288078	Rectal Cancer	Phase 2	Unknown	September 2016	Japan ... 展开 >> Saiseikai Fukuoka General Hospital Recruiting Fukuoka, Japan, 810-0001 Contact: Yasunori Emi, MD, PhD +81-92-771-8151 emi-y@saiseikai-hp.chuo.fukuoka.jp 收起 <<
NCT03347292	Carcinoma, Hepatocellular	Phase 1	Recruiting	February 17, 2021	United States, California ... 展开 >> USC Norris Hospital and Clinics Recruiting Los Angeles, California, United States, 90033 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Recruiting Tampa, Florida, United States, 33612 United States, New York Mount Sinai Medical Center Recruiting New York, New York, United States, 10029 United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109-1023 Germany Universitätsklinikum Köln Not yet recruiting Köln, Nordrhein-Westfalen, Germany, 50937 Universitätsmedizin der Johannes Gutenberg Universität Mainz Not yet recruiting Mainz, Rheinland-Pfalz, Germany, 55131 收起 <<
NCT01187615	Small Cell Lung Carcinoma	Phase 1	Terminated	-	United States, Connecticut ... 展开 >> New Haven, Connecticut, United States, 06519 United States, Nevada Las Vegas, Nevada, United States, 89135-3011 United States, New York New York, New York, United States, 10065 United States, North Carolina Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT02106858	-		Recruiting	May 7, 2019	Korea, Republic of ... 展开 >> Recruiting Multiple Locations, Korea, Republic of 收起 <<
NCT02042144	-		Completed	-	Argentina ... 展开 >> Multiple Locations, Argentina Austria Multiple Locations, Austria Czechia Multiple Locations, Czechia Denmark Multiple Locations, Denmark France Multiple Locations, France Italy Multiple Locations, Italy Luxembourg Multiple Locations, Luxembourg Mexico Multiple Locations, Mexico Netherlands Multiple Locations, Netherlands Singapore Multiple Locations, Singapore Spain Multiple Locations, Spain Switzerland Multiple Locations, Switzerland Taiwan Multiple Locations, Taiwan 收起 <<
NCT03386825	-		Completed	-	Belgium ... 展开 >> Belgium Multiple Locations, Belgium 收起 <<
NCT01318265	Pharmacokinetics	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Brighton, Massachusetts, United States, 02135 收起 <<
NCT02788006	Colorectal Adenocarcinoma	Phase 2	Unknown	May 2018	France ... 展开 >> CHU SUD - Service Oncologie Médicale Recruiting Amiens, France Contact: Bruno CHAUFFERT chauffert.bruno@chu-amiens.fr Principal Investigator: Bruno CHAUFFERT Sub-Investigator: Roxana FOURNIER Sub-Investigator: Sanaa HANNAT CH Victor Dupouy Recruiting Argenteuil, France Contact: Malika BOUDRAOUI malika_boudraoui@yahoo.fr Principal Investigator: Malika BOUDRAOUI Sub-Investigator: Radu VANICA Sub-Investigator: Arnaud BOUTANT-LAROZE Sub-Investigator: Laëticia JOLY Sub-Investigator: Julie BOISSET Sub-Investigator: Djamel GHEBRIOU Hôpital privé Les Bonnettes Recruiting Arras, France Contact: Bruno HUGUENIN drbhuguenin@orange.fr Principal Investigator: Bruno HUGUENIN Sub-Investigator: Anne-Sophie BLANC CH Recruiting Auch, France Contact: Karine SALIGNON K.Salignon@ch-auch.fr Principal Investigator: Karine SALIGNON CH Recruiting Auxerre, France Contact: Anne-Laure VILLING alvilling@ch-auxerre.fr Principal Investigator: Anne-Laure VILLING Clinique Tivoli Ducos Recruiting Bordeaux, France Contact: Nathalie BONICHON-LAMICHHANE bonichon-lamichhane@wanadoo.fr Principal Investigator: Nathalie BONICHON-LAMICHHANE Polyclinique Nord Recruiting Bordeaux, France Contact: Cédric LECAILLE lecail@hotmail.com Principal Investigator: Cédric LECAILLE Sub-Investigator: Xavier MONCOUCY Sub-Investigator: Regis MANNANT Sub-Investigator: Iris DEVAURE Sub-Investigator: Laure DUPONT KAZMA CH Dubois Recruiting Brive La Gaillarde, France Contact: Laure VAYRE laure.vayre@ch-brive.fr Principal Investigator: Laure VAYRE Centre François Bacless Recruiting Caen, France Contact: Aurélie PARZY a.parzy@baclesse.unicancer.fr Principal Investigator: Aurélie PARZY Hôpital privé Sainte Marie Recruiting Chalon sur Saone, France Contact: Adrien MELIS melisadrien@yahoo.fr Principal Investigator: Adrien MELIS Sub-Investigator: Erika VIEL Sub-Investigator: André VANOLI Sub-Investigator: Léa PERRON Centre Oncologie et Radiothérapie Recruiting Dijon, France Contact: Ariane DARUT JOUVE ariane.jouve@orange.fr Principal Investigator: Ariane DARUT JOUVE Sub-Investigator: Genevieve BOILLEAU-JOLIMOY Sub-Investigator: Marie-Christine BONE-LEPINOY Sub-Investigator: Edouard LAGNEAU CHI Recruiting Elbeuf, France Contact: Anne-Marie QUEUNIET anne-marie.queuniet@chi-elbeuf-louviers.fr Principal Investigator: Anne-Marie QUEUNIET CH Marne La Vallée Recruiting Jossigny, France Contact: Christine LE FOLL clefoll@ch-lagny77.fr Principal Investigator: Christine LE FOLL Sub-Investigator: Tamar KUTATELADZE CHD Les Oudairies Recruiting La Roche sur Yon, France Contact: Roger FAROUX roger.faroux@chd-vendee.fr Principal Investigator: Roger FAROUX Sub-Investigator: Morgane AMIL Sub-Investigator: Lucile BAUGUION Sub-Investigator: Cécile GARCEAU Sub-Investigator: Carelle KOUDOUGOU Sub-Investigator: Vincent MACE Sub-Investigator: Matthieu SCHNEE Sub-Investigator: Véronique GIRRE Sub-Investigator: Tifenn L'HARIDON Sub-Investigator: Frank PRIOU Sub-Investigator: Jean-François RAMEE Sub-Investigator: Thierry CHARLOIS Sub-Investigator: Elodie MENAGER TABOUREL Clinique du Cap d'Or Recruiting La Seyne Sur Mer, France Contact: Mounira EL DEMERY oncocco2@gmail.com Principal Investigator: Mounira EL DEMERY Caluire et Cuire - Infirmerie Protestante de Lyon Recruiting Lyon, France Contact: Johannes HARTWIG johannes.hartwig@infirmerie-protestante.com Principal Investigator: Johannes HARTWIG Sub-Investigator: David TAVAN CH Lyon Sud (HCL) - Pierre Benite Recruiting Lyon, France Contact: Claire FALANDRY claire.falandry@chu-lyon.fr Principal Investigator: Claire FALANDRY Sub-Investigator: Marion CHAUVENET Sub-Investigator: Benoît YOU Hôpital privé Jean Mermoz Recruiting Lyon, France Contact: Jérôme DESRAME jerome.desrame@orange.fr Principal Investigator: Jérôme DESRAME Sub-Investigator: Pascal ARTRU Sub-Investigator: Gérard LLEDO Hôpital Européen Recruiting Marseille, France Contact: Yves RINALDI y.rinaldi@hopital-europeen.fr; yrinaldi@wanadoo.fr Principal Investigator: Yves RINALDI Sub-Investigator: Julie GIGOUT Sub-Investigator: Cécile JULIEN CH Recruiting Meaux, France Contact: Christophe LOCHER c-locher@ch-meaux.fr Principal Investigator: Christophe LOCHER Sub-Investigator: Laurence THOMAS-MARQUES Sub-Investigator: Marc PRIETO Sub-Investigator: Hatem SALLOUM CHRU - Hôpital Saint Eloi Recruiting Montpellier, France Contact: Eric ASSENAT e-assenat@chu-montpellier.fr;e.assenat@gmail.com Principal Investigator: Eric ASSENAT Sub-Investigator: Christophe CARENCO Sub-Investigator: Thibault MAZARD Sub-Investigator: Marc YCHOU Sub-Investigator: Catherine GUILLEMARE Clinique d'Occitanie Recruiting Muret, France Contact: Jean-Marie VANTELON jmvantelon@gmail.com Principal Investigator: Jean-Marie VANTELON Hôpital Américain Recruiting Neuilly sur Seine, France Contact: Lionel VEDRINE lionelvedrine@orange.fr Principal Investigator: Lionel VEDRINE Sub-Investigator: Hanah LAMALLEM Sub-Investigator: Marc BOLLET Sub-Investigator: Alain TOLEDANO CHR - Service HGE Recruiting Orléans, France Contact: Barbara DAUVOIS barbara.dauvois@chr-orleans.fr Principal Investigator: Barbara DAUVOIS Sub-Investigator: Jean-Paul LAGASSE Sub-Investigator: Sofia HERRMANN Sub-Investigator: Belinda TCHOUNJEU Saint Joseph Recruiting Paris, France Contact: Nabil BABA HAMED nbaba-hamed@hpsj.fr Principal Investigator: Nabil BABA HAMED Sub-Investigator: Robert SVERDLIN Sub-Investigator: Francesco SAVINELLI Sub-Investigator: Michel GATINEAU Sub-Investigator: Lionel STAUDACHER Sub-Investigator: Eric RAYMOND CH Recruiting Perpignan, France Contact: Faiza KHEMISSA AKOUZ faiza.khemissa@ch-perpignan.fr Principal Investigator: Faiza KHEMISSA AKOUZ Hôpital Haut Leveque Recruiting Pessac, France Contact: Eric TERREBONNE eric.terrebonne@chu-bordeaux.fr Principal Investigator: Eric TERREBONNE Sub-Investigator: Pierre GROUSSEAU Sub-Investigator: Denis SMITH Centre Cario - HPCA Recruiting Plérin, France Contact: Pierre Luc ETIENNE pl.etienne@cario-sante.fr ; pl.etienne@wanadoo.fr Principal Investigator: Pierre Luc ETIENNE Sub-Investigator: Dominique BESSON Sub-Investigator: ANNE-CLAIRE HARDY-BESSARD CH Annecy Genevois Recruiting Pringy, France Contact: Emmanuel MAILLARD emaillard@ch-annecygenevois.fr Principal Investigator: Emmanuel MAILLARD Sub-Investigator: Mathieu BACONNIER Sub-Investigator: Aude MONTCHAUD Sub-Investigator: Laëtitia STEFANI Sub-Investigator: Oana POP CHU Recruiting Saint-Etienne, France Contact: Jean-Marc PHELIP j.marc.phelip@chu-st-etienne.fr Principal Investigator: Jean-Marc PHELIP Sub-Investigator: Nadia BOUARIOUA Sub-Investigator: Léa CLAVEL CHP Recruiting Saint-Grégoire, France Contact: Laurent MIGLIANICO lmiglianico@cpa-sante.com Principal Investigator: Laurent MIGLIANICO Sub-Investigator: Anne MERCIER-BLAS Sub-Investigator: Jerome CHAMOIS Sub-Investigator: Romuald LE SCODAN Centre Paul Strauss Recruiting Strasbourg, France Contact: Meher BEN ABDELGHANI mbenabdelghani@strasbourg.unicancer.fr Principal Investigator: Meher BEN ABDELGHANI Sub-Investigator: Pascal PIEDBOIS Sub-Investigator: Christian BOREL Sub-Investigator: Christine BELLETIER CHI Les Hôpitaux de Léman Recruiting Thonon Les Bains, France Contact: Ahmed BEDJAOUI a-bedjaoui@ch-hopitauxduleman.fr Principal Investigator: Ahmed BEDJAOUI Sub-Investigator: Maria DIAZ-GHANEM Hôpital privé Recruiting Villeneuve D'Ascq, France Contact: Olivier ROMANO romanoolivier@yahoo.fr Principal Investigator: Olivier ROMANO Sub-Investigator: Nathalie LEMOINE 收起 <<
NCT02386397	Digestive Cancer	Phase 1 Phase 2	Recruiting	April 2019	France ... 展开 >> Centre Val d'Aurelle Recruiting Montpellier, France, 34298 Principal Investigator: Eric ASSENAT, MD 收起 <<
NCT02368886	Colon Adenocarcinoma ... 展开 >> Rectal Adenocarcinoma Stage III Colorectal Cancer AJCC v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 收起 <<	Phase 2	Active, not recruiting	June 22, 2019	-
NCT01298570	-		Active, not recruiting	-	-
NCT03564938	Colorectal Neoplasms	Phase 4	Recruiting	October 19, 2020	India ... 展开 >> HCG-City Cancer Centre Not yet recruiting Vijayawada, Andhra Pradesh, India, 520004 BLK Super Speciality Hospital Not yet recruiting New Delhi, Delhi, India, 11005 Sir Ganga Ram Hospital Not yet recruiting New-Delhi, Delhi, India, 110060 The Gujarat Cancer & Research Institute Not yet recruiting Ahmedabad, Gujarat, India, 380016 Manipal Hospital Not yet recruiting Bangalore, Karnataka, India, 560017 Healthcare Global Enterprises Ltd Not yet recruiting Bangalore, Karnataka, India, 560027 Tata Memorial Hospital Recruiting Mumbai, Maharashtra, India, 400012 Fortis Hospital Not yet recruiting West-Mumbai, Maharashtra, India, 400078 Health Point Hospital Not yet recruiting Kolkata, West Bengal, India, 700025 Indraprastha Apollo Hospital Not yet recruiting New Delhi, India 收起 <<
NCT01265979	-		Completed	-	Belgium ... 展开 >> Radiology Department Leuven, Belgium, 3000 收起 <<
NCT01298570	Colorectal Cancer Metastatic	Phase 2	Active, not recruiting	February 2019	United States, Colorado ... 展开 >> Rocky Mountain Cancer Centers Denver, Colorado, United States, 80218 United States, Florida Mount Sinai Medical Center-Miami Miami, Florida, United States, 33140 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 Georgia Cancer Specialists Atlanta, Georgia, United States, 30341 United States, Indiana Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Kentucky University of Louisville James Brown Cancer Center Louisville, Kentucky, United States, 40202 United States, New York North Shore Long Island Jewish Health System Manhasset, New York, United States, 11030 New York University Langone Medical Center New York, New York, United States, 10016 United States, North Carolina Seby B. Jones Cancer Center Boone, North Carolina, United States, 28607 University of North Carolina Chapel Hill, North Carolina, United States, 27599 Carolinas HealthCare System Charlotte, North Carolina, United States, 28262 Southeast Medical Oncology Center Goldsboro, North Carolina, United States, 27534 The Moses Cone Regional Cancer Center Greensboro, North Carolina, United States, 27403 Leo W. Jenkins Cancer Center at ECU Medical School Greenville, North Carolina, United States, 27834 First Health of the Carolinas, Moore Regional Hospital Pinehurst, North Carolina, United States, 28374 Rex Cancer Center at Rex Hospital Raleigh, North Carolina, United States, 27607 Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43221 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22903 Portsmouth Naval Medical Center Portsmouth, Virginia, United States, 23708 United States, Washington Multicare Regional Cancer Center Tacoma, Washington, United States, 98405 Ireland Ireland Cooperative Clinical Research Group Dublin, Ireland 收起 <<
NCT01896856	Previously Treated Metastatic ... 展开 >>Colorectal Cancer 收起 <<	Phase 2	Recruiting	September 2019	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Anthony El-Khoueiry, MD 323-865-3967 elkhouei@med.usc.edu United States, Maryland Sidney Kimmel Comprehensive Cancer Center Recruiting Baltimore, Maryland, United States, 21231 Contact: Ellen Lilly-Foreman, RN 443-287-4961 lillyel@jhmi.edu Contact: Tearra Miles tlawre18@jhmi.edu Principal Investigator: Nilo Azad, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Derek Alexander 646-888-1381 alexandd@mskcc.org Principal Investigator: Andrea Cercek, MD Netherlands VU Medisch Centrum Recruiting Amsterdam, Netherlands, 1081 HV Contact: Henk Verheul, MD h.verheul@vumc.nl Contact: Elske Gootjes, MD e.gootjes@vumc.nl 收起 <<
NCT02835924	Metastatic Colorectal Cancer	Phase 2	Active, not recruiting	January 2019	Spain ... 展开 >> Spanish Cooperative Group for the Treatment of Digestive Tumors Madrid, Spain, 28007 收起 <<
NCT03081494	Metastatic Colorectal Cancer	Phase 1	Recruiting	February 28, 2019	Australia, New South Wales ... 展开 >> Novartis Investigative Site Active, not recruiting St Leonards, New South Wales, Australia, 2065 Australia, Western Australia Novartis Investigative Site Active, not recruiting Murdoch, Western Australia, Australia, 6150 Canada, Quebec Novartis Investigative Site Completed Montreal, Quebec, Canada, H3T 1E2 France Novartis Investigative Site Completed Toulouse Cedex 9, France, 31059 Israel Novartis Investigative Site Recruiting Tel Aviv, Israel, 64239 Italy Novartis Investigative Site Withdrawn Milano, MI, Italy, 20162 Novartis Investigative Site Withdrawn Rozzano, MI, Italy, 20089 Japan Novartis Investigative Site Completed Kashiwa, Chiba, Japan, 277-8577 Korea, Republic of Novartis Investigative Site Active, not recruiting Seoul, Korea, Korea, Republic of, 05505 Netherlands Novartis Investigative Site Recruiting Leiden, Netherlands, 2333 ZA Singapore Novartis Investigative Site Completed Singapore, Singapore, 169610 Spain Novartis Investigative Site Completed Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Terminated Madrid, Spain, 28040 Novartis Investigative Site Completed Madrid, Spain, 28041 收起 <<
NCT01959269	-		Completed	-	Germany ... 展开 >> Multiple Locations, Germany 收起 <<
NCT01786538	Metastatic Colorectal Cancer	Phase 3	Withdrawn	May 2017	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Songpa-gu, Korea, Republic of, 138736 收起 <<
NCT02656524	-		Completed	-	Hungary ... 展开 >> Budapest, Hungary 收起 <<
NCT03644511	-		Not yet recruiting	December 31, 2021	Germany ... 展开 >> Many Locations Not yet recruiting Multiple Locations, Germany 收起 <<
NCT02241720	Upper GI Cancer	Phase 2	Terminated(Low Accrual)	-	United States, Utah ... 展开 >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 收起 <<
NCT02584465	Ovarian Carcinoma	Phase 2	Recruiting	May 2022	France ... 展开 >> ICO Paul Papin Active, not recruiting Angers, France, 49100 Institut Sainte-Catherine Active, not recruiting Avignon, France, 84918 Hôpital Jean Minjoz Active, not recruiting Besancon, France, 25030 Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Anne FLOQUET, MD 5 56 33 33 33 ext 0033 a.floquet@bordeaux.unicancer.fr Polyclinique Bordeaux Nord Active, not recruiting Bordeaux, France, 33300 Centre François Baclesse Enrolling by invitation Caen, France, 14000 Centre Hospitalier de Cholet Active, not recruiting Cholet, France, 49300 Centre Jean Perrin Enrolling by invitation Clermont-ferrand, France, 63000 Centre Oscar Lambret Active, not recruiting Lille, France, 59020 Centre Hospitalier Universitaire Dupuytren Enrolling by invitation Limoges, France, 87042 Centre Léon Bérard Recruiting Lyon, France, 69373 Contact: Olivier TREDAN, MD 4 78 78 59 16 ext 0033 olivier.tredan@lyon.unicancer.fr Institut Paoli Calmettes Recruiting Marseille, France, 13009 Contact: Magali PROVANSAL, MD 4 91 22 37 40 ext 0033 provansalm@ipc.unicancer.fr Hôpital de Mont-de-Marsan Active, not recruiting Mont de Marsan, France, 40024 Centre Azuréen de Cancérologie Recruiting Mougins, France, 06250 Contact: Rémy LARGILLIER 4 92 92 37 37 ext 0033 r.largillier@cac-mougins.fr ORACLE - Centre d'Oncologie de Gentilly Active, not recruiting Nancy, France, 54100 Centre Catherine de Sienne Recruiting Nantes, France, 44202 Contact: Alain LORTHOLARY, MD 2 28 27 21 71 ext 0033 lortholary.alain@catherinedesienne.fr Centre Hospitalier Régional d'Orléans Active, not recruiting Orléans, France, 45067 Institut Mutualiste Montsouris Recruiting Paris, France, 75014 Contact: Chrostophe LOUVET, MD 1 56 61 60 35 ext 0033 christophe.louvet@imm.fr Clinique Francheville Active, not recruiting Perigueux, France, 24004 Centre Hospitalier Lyon Sud Active, not recruiting Pierre-Benite, France, 69495 Centre CARIO - HPCA Recruiting Plerin SUR MER, France, 22190 Contact: Anne-Claire HARDY-BESSARD, MD 2 96 75 22 16 ext 0033 ac.hardy@clin-armoricaine.fr Centre Hospitalier Annecy Genevois Active, not recruiting Pringy, France, 74374 Institut Jean Godinot Recruiting Reims, France, 51056 Contact: Aude-Marie SAVOYE, MD 26 50 43 97 ext +33(0)4 aude-marie.savoye@reims.unicancer.fr ICO Centre René Gauducheau Active, not recruiting Saint-herblain, France, 44805 Centre de Radiothérapie - Clinique Sainte-Anne Active, not recruiting Strasbourg, France, 67000 Centre Paul Strauss Active, not recruiting Strasbourg, France, 67065 Centre Hospitalier Universitaire Bretonneau Active, not recruiting Tours, France, 37044 收起 <<
NCT02389244	Ewing Sarcomas ... 展开 >> Chondrosarcomas Osteosarcomas Chondroma 收起 <<	Phase 2	Recruiting	March 2021	France ... 展开 >> Hopital Jean Monjoz Not yet recruiting Besancon, France, 25030 Principal Investigator: Elsa KALBACHER, MD Institut Bergonie Recruiting Bordeaux, France, 33076 Principal Investigator: Antoine ITALIANO, MD Centre Francois Baclesse Recruiting Caen, France, 14176 Principal Investigator: Corinne DELCAMBRE, MD Centre Georges Francois Leclerc Recruiting Dijon, France, 21079 Principal Investigator: Nicolas ISAMBERT, MD Centre Oscar Lambret Recruiting Lille, France, 59020 Principal Investigator: Nicolas PENEL, MD Centre Léon Berard Recruiting Lyon, France, 69373 Principal Investigator: Jean Yves BLAY, MD PhD Institut Paoli Calmettes Recruiting Marseille, France, 13273 Principal Investigator: François BERTUCCI, MD PhD La Timone University Hospital Recruiting Marseille, France, 13385 Principal Investigator: Florence DUFFAUD, MD PhD ICM Val d'Aurelle Recruiting Montpellier, France, 34298 Principal Investigator: Didier CUPISSOL, MD Centre Antoine Lacassagne Recruiting Nice, France, 06189 Principal Investigator: Antoine THYSS, MD PhD Hôpital Cochin Recruiting Paris, France, 75014 Principal Investigator: Pascaline BOUDOU-ROUQUETTE, MD Institut Curie Recruiting Paris, France Principal Investigator: Sophie PIPERNO-NEUMANN, MD Centre Eugene Marquis Recruiting Rennes, France, 35042 Principal Investigator: Christophe PERRIN, MD Institut de cancerologie de l'ouest site Rene Gauducheau Recruiting Saint Herblain, France, 44805 Principal Investigator: Emmanuelle BOMPAS, MD Institut de Cancérologie Lucien Neuwirth (ICLN) Recruiting Saint Priest en Jarez, France, 42270 Principal Investigator: Olivier COLLARS, MD Institut Claudius Regaud Recruiting Toulouse, France, 31052 Principal Investigator: Christine CHEVREAU, MD CHU Bretonneau Recruiting Tours, France, 37000 Principal Investigator: Helene VEGAS, MD Institut de cancerologie de lorraine alexis Vautrin Recruiting Vandoeuvre les Nancy, France, 54519 Principal Investigator: Maria RIOS, MD Gustave Roussy Recruiting Villejuif, France, 94800 Principal Investigator: Olivier MIR, MD 收起 <<
NCT02234180	-		Terminated	-	-
NCT02234180	Adenocarcinoma of the Gastroes... 展开 >>ophageal Junction Stage IIB Esophageal Adenocarcinoma Stage IIIA Esophageal Adenocarcinoma Stage IIIB Esophageal Adenocarcinoma Stage IIIC Esophageal Adenocarcinoma 收起 <<	Phase 2	Terminated	-	United States, Illinois ... 展开 >> Carle Cancer Center Urbana, Illinois, United States, 61801 United States, Kansas Cancer Center of Kansas - Wichita Wichita, Kansas, United States, 67214 United States, Louisiana Ochsner Medical Center Jefferson New Orleans, Louisiana, United States, 70121 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Nebraska Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68106 United States, New Hampshire Dartmouth Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States, 27157 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Toledo Clinic Cancer Centers-Toledo Toledo, Ohio, United States, 43623 收起 <<
NCT01339104	Neoplasms	Phase 1	Completed	-	United States, Colorado ... 展开 >> Aurora, Colorado, United States, 80010 United States, Michigan Ann Arbor, Michigan, United States, 48109 United States, Missouri St. Louis, Missouri, United States, 63110 United States, Oklahoma Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Washington Seattle, Washington, United States, 98109 收起 <<
NCT01774344	Carcinoma, Hepatocellular	Phase 3	Active, not recruiting	February 28, 2019	-
NCT02241720	-		Terminated(Low Accrual)	-	-
NCT01913639	Esophageal Cancer ... 展开 >> Gastric Cancer 收起 <<	Phase 2	Active, not recruiting	July 2019	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital Sleepy Hollow, New York, United States 收起 <<
NCT03305913	Pretreated Metastatic Colorect... 展开 >>al Cancer 收起 <<	Phase 1	Recruiting	June 30, 2019	Germany ... 展开 >> Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik Recruiting Mainz, Germany, 55131 Contact: Markus Möhler, Prof. Dr. 收起 <<
NCT01774344	-		Active, not recruiting	-	-
NCT02910843	Rectal Cancer	Phase 1	Recruiting	December 2022	Switzerland ... 展开 >> St. Claraspital Basel Recruiting Basel, Switzerland, 4016 Contact: Dieter Köberle, MD +41 61 685 85 85 dieter.koeberle@claraspital.ch Principal Investigator: Dieter Köberle, MD Universitätsspital Basel Recruiting Basel, Switzerland, 4031 Contact: Viviane Hess, Prof +41 61 265 50 74 viviane.hess@usb.ch Principal Investigator: Viviane Hess, Prof Inselspital Bern Recruiting Bern, Switzerland, 3010 Contact: Martin D. Berger, MD +41 31 632 41 14 martin.berger@insel.ch Principal Investigator: Martin D. Berger, MD Kantonsspital Graubünden Recruiting Chur, Switzerland, 7000 Contact: Ioannis Metaxas, MD +41 81 256 66 46 ioannis.metaxas@ksgr.ch Principal Investigator: Ioannis Metaxas, MD Kantonsspital Luzern Recruiting Luzern, Switzerland, 6000 Contact: Ralph Winterhalder, MD +41 41 205 58 75 ralph.winterhalder@ksl.ch Principal Investigator: Ralph Winterhalder, MD Kantonsspital St. Gallen Recruiting St. Gallen, Switzerland, 9007 Contact: Markus Jörger, MD +41 71 494 29 22 markus.joerger@kssg.ch Principal Investigator: Markus Jörger, MD UniversitätsSpital Zürich Recruiting Zurich, Switzerland, 8091 Contact: Bernhard Pestalozzi, Prof +41 (0)44 255 34 40 bernhard.pestalozzi@usz.ch Principal Investigator: Bernhard Pestalozzi, Prof 收起 <<
NCT02347852	-		Completed	-	Austria ... 展开 >> Klinikum Kreuzschwestern Wels GmbH Multiple Locations, Austria, 4600 收起 <<
NCT03099486	Colorectal Cancer	Phase 2	Recruiting	October 22, 2020	United States, Pennsylvania ... 展开 >> Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Wafik El-Deiry, MD 215-214-1515 收起 <<
NCT01973868	Neoplasms	Phase 1	Completed	-	United States, California ... 展开 >> University of Southern California Los Angeles, California, United States, 90033 United States, Colorado University of Colorado Hospital Aurora, Colorado, United States, 80045 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Pennsylvania University of Pittsburgh Medical Center Health System Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT02619435	Advanced Colorectal Cancer	Phase 2	Recruiting	November 2018	Italy ... 展开 >> AO G. Rummo Not yet recruiting Benevento, Italy Istituto Nazionale Tumori Fondazione G. Pascale Recruiting Napoli, Italy Seconda Università di Napoli Not yet recruiting Napoli, Italy AO S. Carlo Not yet recruiting Potenza, Italy 收起 <<
NCT02168777	-		Terminated	-	-
NCT02096354	Colorectal Neoplasms	Phase 2	Active, not recruiting	January 2019	United States, California ... 展开 >> UCSD Moores Cancer Center La Jolla, California, United States, 92093 Stanford University Stanford, California, United States, 94305 United States, Hawaii Kaiser Permanete Honolulu, Hawaii, United States, 96819 United States, Maryland Walter Reed National Military Medical Center Bethesda, Maryland, United States, 20889 Aquilino Cancer Center, Maryland Oncology and Hematology PA Rockville, Maryland, United States, 20850 收起 <<
NCT03520842	KRAS Gene Mutation ... 展开 >> Metastatic Malignant Neoplasm in the Brain Recurrent Non-Small Cell Lung Carcinoma Stage IV Non-Small Cell Lung Cancer AJCC v7 收起 <<	Phase 2	Recruiting	June 1, 2020	United States, California ... 展开 >> Stanford University School of Medicine Recruiting Palo Alto, California, United States, 94304 Contact: Vivian Tsang 650-723-0186 tsangv@stanford.edu Principal Investigator: Sukhmani Padda 收起 <<
NCT02773524	Gastro-Oesophageal Cancer	Phase 3	Recruiting	December 2021	-
NCT02168777	Neoplasms	Phase 1	Terminated	-	United States, Connecticut ... 展开 >> New Haven, Connecticut, United States, 06510 United States, Michigan Detroit, Michigan, United States, 48201 United States, Missouri Saint Louis, Missouri, United States, 63110 United States, North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Texas Houston, Texas, United States, 77030 收起 <<
NCT02406170	Esophageal Neoplasms ... 展开 >> Stomach Neoplasms Neoplasm Metastasis 收起 <<	Phase 1 Phase 2	Recruiting	April 2019	Netherlands ... 展开 >> Academic Medical Center, Medical Oncology Recruiting Amsterdam, Netherlands, 1100 DD Contact: H WM van Laarhoven, MD, PhD, PhD 31 20 5665955 h.vanlaarhoven@amc.uva.nl Contact: E. H. vandaalen 31 20 5668229 trialmedonc@amc.uva.nl Principal Investigator: H. WM van Laarhoven, MD, PhD, PhD Sub-Investigator: S O. van der Woude, MD 收起 <<
NCT02175654	Colorectal Neoplasms ... 展开 >> Metastatic Disease 收起 <<	Phase 2	Terminated(The trial was prema... 展开 >>turely closed due to lack of accrual) 收起 <<	-	Spain ... 展开 >> Spanish Cooperative Group for Digestive Tumour Therapy (TTD) Madrid, Spain, 28046 收起 <<
NCT02001909	Neoplasms	Phase 1	Completed	-	Germany ... 展开 >> Berlin, Germany, 13353 收起 <<
NCT02278783	Ovarian Cancer ... 展开 >> Primary Peritoneal Cancer Fallopian Tube Cancer 收起 <<	Phase 2	Terminated(Slow Accrual)	-	United States, Utah ... 展开 >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 收起 <<
NCT02398513	Oncology	Phase 1	Completed	-	China ... 展开 >> Shanghai, China, 200032 收起 <<
NCT02199223	KRAS and NRAS Wild-type Colore... 展开 >>ctal Cancer 收起 <<	Phase 1	Terminated(Slow accrual)	-	United States, Utah ... 展开 >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 收起 <<
NCT03465722	GIST	Phase 3	Recruiting	April 2023	-
NCT01875380	Colorectal Neoplasms ... 展开 >> Metastatic Disease 收起 <<	Phase 2	Completed	-	Spain ... 展开 >> Spanish Cooperative Group for Digestive Tumour Therapy (TTD) Madrid, Spain, 28046 收起 <<
NCT02098538	Adenoid Cystic Carcinoma	Phase 2	Active, not recruiting	March 2019	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States 收起 <<
NCT02048722	Adult Angiosarcoma ... 展开 >> Recurrent Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma 收起 <<	Phase 2	Recruiting	February 2020	United States, California ... 展开 >> Sarcoma Oncology Center Recruiting Santa Monica, California, United States, 90403 Contact: Sant P. Chawla, M.D. FRACP 310-552-9999 Principal Investigator: Sant P. Chawla, M.D. FRACP United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Steven Attia, DO 904-953-7292 Principal Investigator: Steven Attia, DO United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Mark Agulnik 312-695-1222 m-agulnik@northwestern.edu Principal Investigator: Mark Agulnik United States, Iowa University of Iowa Recruiting Iowa City, Iowa, United States, 52246 Contact: Mohammed M. Milhem 319-356-2324 mohammed-milhem@uiowa.edu Principal Investigator: Mohammed M. Milhem United States, Minnesota University of Minnesota Medical Center-Fairview Not yet recruiting Minneapolis, Minnesota, United States, 55455 Contact: Keith M. Skubitz 612-625-5109 skubi001@umn.edu Principal Investigator: Keith M. Skubitz Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Scott H. Okuno, MD United States, Missouri Washington University-St. Louis Recruiting Saint Louis, Missouri, United States, 63110 Contact: Brian A. Van Tine, MD, PhD 314-747-8475 Principal Investigator: Brian A. Van Tine 收起 <<
NCT02287727	Rectal Adenocarcinoma ... 展开 >> Stage IIA Rectal Cancer Stage IIB Rectal Cancer Stage IIC Rectal Cancer Stage IIIA Rectal Cancer Stage IIIB Rectal Cancer 收起 <<	Phase 2	Withdrawn	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 University of Rochester Medical Center - Wilmont Cancer Institute Rocherster, New York, United States, 14642 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT02278783	-		Terminated(Slow Accrual)	-	-
NCT02195011	Colorectal Neoplasms	Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists - North Saint Petersburg, Florida, United States, 33705 United States, Missouri Research Medical Center Kansas City, Missouri, United States, 64132 United States, Tennessee Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 收起 <<
NCT02195011	-		Completed	-	-
NCT02080260	Pancreatic Cancer	Phase 2	Completed	-	United States, North Carolina ... 展开 >> Levine Cancer Institute-Albemarle Albemarle, North Carolina, United States, 28001 Levine Cancer Institute-South Tryon Charlotte, North Carolina, United States, 28203 Levine Cancer Institute Charlotte, North Carolina, United States, 28204 Levine Cancer Institute - Pineville Charlotte, North Carolina, United States, 28210 Levine Cancer Institute - Southpark Charlotte, North Carolina, United States, 28211 Levine Cancer Institute - Mallard Creek Charlotte, North Carolina, United States, 28262 Levine Cancer Institute - University Charlotte, North Carolina, United States, 28262 Levine Cancer Institute - Ballantyne Charlotte, North Carolina, United States, 28277 Levine Cancer Institute - Concord Concord, North Carolina, United States, 28025 Levine Cancer Institute-Monroe Monroe, North Carolina, United States, 28112 Levine Cancer Institute - Cleveland Shelby, North Carolina, United States, 28150 United States, South Carolina Low Country Hematology Oncology Charleston, South Carolina, United States, 29406 收起 <<
NCT03698253	Colorectal Cancer	Not Applicable	Completed	-	Taiwan ... 展开 >> Chung-Ho Memorial Hospital, Kaohsiung Medical University: Kaohsiung, Taiwan, 807 收起 <<
NCT02383433	Metastatic Pancreatic Adenocar... 展开 >>cinoma 收起 <<	Phase 2	Active, not recruiting	September 1, 2019	United States, Ohio ... 展开 >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 收起 <<
NCT01068769	-		Active, not recruiting	-	-
NCT01068769	Gastrointestinal Stromal Tumor	Phase 2	Active, not recruiting	December 2018	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Oregon Oregon Health Sciences University Portland, Oregon, United States, 97239 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT02501551	Melanoma	Phase 2	Recruiting	June 2019	Korea, Republic of ... 展开 >> Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of, 120-752 Contact: Sang Joon Shin 收起 <<
NCT03289273	-		Recruiting	October 1, 2022	-
NCT02638766	Gastrointestinal Stromal Tumor... 展开 >>s 收起 <<	Phase 2	Recruiting	November 2020	Italy ... 展开 >> Policlinico San Orsola Malpighi Not yet recruiting Bologna, Italy Principal Investigator: Guido Biasco A. O. Careggi Not yet recruiting Firenze, Italy Principal Investigator: Silvia Gasperoni Fondazione IRCCS Istituto Dei Tumori di Milano Not yet recruiting Milan, Italy Principal Investigator: Paolo G. Casalli Istituto Clinico Humanitas Milano Not yet recruiting Milan, Italy Principal Investigator: Armando Santoro Istituto Nazionale Tumori IRCSS "Fondazione G. Pascale" Not yet recruiting Naples, Italy Principal Investigator: Gaetano Apice A. O. Universitaria Policlinico Paolo Giaccone Not yet recruiting Palermo, Italy Principal Investigator: Giuseppe Badalamenti Policlinico Universitario Campus Bio-Medico Not yet recruiting Roma, Italy Principal Investigator: Bruno Vincenzi Istituto di Candiolo - IRCSS Not yet recruiting Torino, Italy Principal Investigator: Giovanni Grignani Spain Hospital Universitario de Canarias Recruiting La Laguna, Santa Cruz de Tenerife, Spain, 38320 Principal Investigator: Claudia Valverde, MD Hospital de Cruces Not yet recruiting Barakaldo, Spain, 48902 Principal Investigator: Natalia Fuente, MD Hospital Universitario Vall d´hebron Recruiting Barcelona, Spain, 08035 Principal Investigator: Claudia Valverde, MD Hospital de la Santa Creu i Sant Pau Recruiting Barcelona, Spain, 08041 Principal Investigator: A. Lopez Pousa, MD Hospital Universitario Gregorio Marañon Not yet recruiting Madrid, Spain, 28009 Principal Investigator: Rosa Alvarez, MD Hospital Universitario La Paz Recruiting Madrid, Spain, 28046 Principal Investigator: Virginia Martinez Marín, MD Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain, 41013 Principal Investigator: Javier Martín-broto, MD Hospital Universitario Virgen de la Macarena Recruiting Sevilla, Spain, 41071 Principal Investigator: David Vicente Baz, MD Instituto Valenciano de Oncología Not yet recruiting Valencia, Spain, 46009 Principal Investigator: Andres Poveda, MD Hospital Universitario Miguel Servet Not yet recruiting Zaragoza, Spain, 50009 Principal Investigator: Javier Martinez Trufero, MD 收起 <<
NCT01843400	-		Completed	-	Japan ... 展开 >> Multiple Locations, Japan 收起 <<
NCT03657641	Colorectal Cancer ... 展开 >> Colorectal Cancer Metastatic 收起 <<	Phase 1 Phase 2	Not yet recruiting	February 25, 2022	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Not yet recruiting Los Angeles, California, United States, 90033 Contact: Xiomara Menendez, RN 323-409-4368 Xiomara.Menendez@med.usc.edu Principal Investigator: Afsaneh Barzi, MD Hoag Memorial Hospital Not yet recruiting Newport Beach, California, United States, 92663 Contact: Alicia L. Bogardus, MA Alicia.bogardus@hoag.org Principal Investigator: Diana L. Hanna, MD United States, Florida Moffitt Cancer Center Not yet recruiting Tampa, Florida, United States, 33612 Contact: Richard D. Kim, MD Richard.Kim@moffitt.org Principal Investigator: Richard D. Kim, MD 收起 <<
NCT02164240	Gastrointestinal Stromal Tumor	Phase 1	Active, not recruiting	May 2020	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02926222	Glioblastoma Multiforme	Phase 2	Active, not recruiting	October 2018	Italy ... 展开 >> IRCCS "Saverio de Bellis Castellana Grotte, BA, Italy, 70013 Ospedale di Bellaria Bologna, BO, Italy Azienda Ospedaliera "G.Rummo" Benevento, BR, Italy istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori Cesena, FC, Italy, 47014 Istituto Neurologico C. Besta IRCCS Milano, MI, Italy, 20133 Istituto Oncologico Veneto IRCCS, Oncologia Medica 1 Padova, PD, Italy, 35128 Ospedale Santa Chiara Pisa, PI, Italy, 56126 Azienda Ospedaliero Universitaria S. Maria della Misericordia Udine, UD, Italy, 33100 Istituto Nazionale Tumori Regina Elena Roma, Italy, 00144 Azienda Ospedaliera Universitaria Città della Salute e della Scienza Torino, Italy, 10126 收起 <<
NCT01900743	Sarcoma	Phase 2	Active, not recruiting	March 31, 2019	Austria ... 展开 >> Medizinische Universität Graz Graz, Austria, 8036 Universitätsklinik für Innere Medizin I Innsbruck, Austria, 6020 LKH Klagenfurt, Austria Krankenhaus der Barmherzigen Schwestern Linz Linz, Austria, 4010 AKH-Wien Wien, Austria, 1090 France Hôpital St Jacques Besancon, France, 25000 Institut Bergonié Bordeaux, France, 33076 Centre François Baclesse Caen, France, 14076 Centre GF Leclercq Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Institut Paoli Calmettes Marseille, France, 13273 Hôpital de La Timone Marseille, France, 13354 Centre René Gauducheau Nantes, France, 44805 Centre Antoine Lacassagne Nice, France, 06189 Institut Curie Paris, France, 75005 Hôpital Saint Louis Paris, France, 75010 Hôpital Cochin Paris, France, 75014 Centre Eugène Marquis Rennes, France, 35042 Centre Henri Becquerel Rouen, France, 76038 Institut Curie - Hôpital René Huguenin Saint Cloud, France, 92210 Institut de Cancérologie Lucien Neuwirth (ICL) St Priest En Jarez, France, 42270 Institut Claudius Regaud Toulouse, France, 32052 Centre Alexis Vautrin Vandoeuvre Les Nancy, France, 54519 Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT01853046	-		Completed	-	-
NCT01853046	Neoplasms	Phase 1	Completed	-	United States, California ... 展开 >> Los Angeles, California, United States, 90033 United States, Colorado Aurora, Colorado, United States, 80045 United States, Missouri St. Louis, Missouri, United States, 63110 United States, New Hampshire Lebanon, New Hampshire, United States, 03756 United States, New York Buffalo, New York, United States, 14263-0001 Canada, Alberta Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Hamilton, Ontario, Canada, L8V 5C2 Canada, Quebec Montreal, Quebec, Canada, H2L 4M1 收起 <<
NCT02889328	Gastrointestinal Stromal Tumor... 展开 >>s (GISTs) 收起 <<	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea, Republic of, 138-736 收起 <<
NCT02162914	Cholangiocarcinoma	Phase 2	Unknown	December 2016	Belgium ... 展开 >> CH Jolimont Active, not recruiting Haine-Saint-Paul, Hainaut, Belgium, 7100 University Hospitals of Antwerp Not yet recruiting Antwerp, Belgium, 2650 Contact: Marc Peeters, MD, PhD +32(0)38213954 marc.peeters@uza.be Contact: Iris Verhaegen +32(0)8215681 iris.verhaegen@uza.be Principal Investigator: Marc Peeters, MD, PhD AZ St-Lucas Brugge Not yet recruiting Brugge, Belgium, 8310 Contact: Joris Arts, MD +32(0)50 36 57 11 joris.arts@stlucas.be Contact: Hilde Nevens, Mrs +32(0)50 36 57 11 hilde.nevens@stlucas.be Principal Investigator: Joris Arts, MD Erasme University Hospital Recruiting Brussels, Belgium, 1070 Contact: Anne Demols, MD, PhD +32(0)25555867 anne.demols@erasme.ulb.ac.be Principal Investigator: Anne Demols, MD, PhD Cliniques Universitaires Saint-Luc Recruiting Brussels, Belgium, 1200 Contact: Ivan Borbath, MD, PhD +32 (0)2 764 4213 ivan.borbath@uclouvain.be Contact: Antonino Ceratti, Mr +32 (0)2 764 4213 antonino.ceratti@uclouvain.be Principal Investigator: Ivan Borbath, MD, PhD Grand Hôpital de Charleroi Active, not recruiting Charleroi, Belgium, 6000 AZ St-Lucas Gent Not yet recruiting Gent, Belgium, 9000 Contact: Johan Van Ongeval, MD +32(0)9/2246111 johan.VanOngeval@AZSTLUCAS.be Contact: Koen De Graeve, Mr +32(0)9/224 62 27 koen.degraeve@azstlucas.be Principal Investigator: Johan Van Ongeval, MD UZ Gent Not yet recruiting Gent, Belgium, 9000 Contact: Stéphanie Laurent, MD, PhD 09/3322371 Contact: Roxane Van Vynckt, Mrs +32(0)9/3322378 roxane.vanvynckt@uzgent.be Principal Investigator: Stéphanie Laurent, MD, PhD CHC St-Joseph Active, not recruiting Liège, Belgium, 4000 Hôpital Ambroise Paré Not yet recruiting Mons, Belgium, 7000 Contact: Stephane Holbrechts, MD +32(0)65/39 39 39 stephane.holbrechts@hap.be Contact: Melissa Canzurlo, Mrs +32(0)65/39 39 39 melissa.canzurlo@hap.be Principal Investigator: Stephane Holbrechts, MD AZ Delta Not yet recruiting Roeselare, Belgium, 8800 Contact: Jochen Decaestecker, MD +32(0)51/237111 jdecaestecker@azdelta.be Contact: Sophie Adriaens, Mrs +32(0)51/237111 sadriaens@azdelta.be Principal Investigator: Jochen Decaestecker, MD 收起 <<
NCT02699073	Metastatic Colorectal Cancer	Phase 2	Recruiting	December 2018	France ... 展开 >> CHU Jean Minjoz Recruiting Besançon, France Contact: Kim STEFANO, MD Hôpitlal Henri Mondor Recruiting Créteil, France Contact: Benoit ROUSSEAU, MD Institut Hospitalier Franco-Britannique Recruiting Levallois Perret, France Contact: Benoist CHIBAUDEL, MD CHRU Claude Huriez Not yet recruiting Lille, France Contact: Mohamed HEBBAR, MD ICM Val D'Aurelle Recruiting Montpellier, France Contact: Thibault MAZARD, MD Hôpital Pitié Salpêtrière Recruiting Paris, France Contact: Jean Baptiste BACHET, MD Hôpital Saint Antoine Recruiting Paris, France Contact: Thierry ANDRE, MD Insitut Mutualiste Montouris Recruiting Paris, France Contact: Jean Luc MOLITOR, MD 收起 <<
NCT02310477	-		Completed	-	France ... 展开 >> Centre Oscar Lambret Lille, France, 59020 收起 <<
NCT01853319	Colorectal Neoplasms	Phase 3	Completed	-	Turkey ... 展开 >> Ankara, Turkey, 06100 Ankara, Turkey, 06500 Antalya, Turkey Balcali/Adana, Turkey, 01330 Bursa, Turkey Gaziantep, Turkey, 27010 Istanbul, Turkey, 34093 Istanbul, Turkey, 34899 Izmir, Turkey, 35100 Kayseri, Turkey Samsun, Turkey 收起 <<
NCT02023333	Metastatic Colorectal Adenocar... 展开 >>cinoma 收起 <<	Phase 2	Active, not recruiting	December 2019	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge, New Jersey, United States United States, New York Downstate Medical Center Brooklyn, New York, United States, 11203 Memorial Sloan Kettering Cancer Center at Commack Commack, New York, United States, 11725 Queens Cancer Center of Queens Hospital Jamaica, New York, United States, 11432 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 Memorial Sloan Kettering Cancer Center Sleepy Hollow Sleepy Hollow, New York, United States, 10591 收起 <<
NCT02053376	Metastatic Biliary Tract Carci... 展开 >>noma 收起 <<	Phase 2	Active, not recruiting	October 21, 2018	United States, Pennsylvania ... 展开 >> Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT02800330	Colorectal Neoplasms ... 展开 >> Gastrointestinal Stromal Tumors 收起 <<	Phase 4	Completed	-	Netherlands ... 展开 >> Erasmus Medical Center Rotterdam, South Holland, Netherlands, 3015 CE 收起 <<
NCT03475953	Colorectal Cancer Not MSI-H or... 展开 >> MMR-deficient GIST Oesophageal or Gastric Carcinoma Biliary Tract Cancer Hepatocellular Carcinoma 收起 <<	Phase 1 Phase 2	Recruiting	April 2021	France ... 展开 >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Sophie COUSIN, MD Principal Investigator: Sophie COUSIN, MD Sub-Investigator: Antoine ITALIANO, MD, PhD Institut de Cancérologie de Montpellier Not yet recruiting Montpellier, France, 34298 Contact: Antoine ADENIS, MD, PhD IUCT Oncopôle - Institut Claudius Regaud Not yet recruiting Toulouse, France, 31059 Contact: Carlos GOMEZ-ROCA, MD 收起 <<
NCT02259725	Gastrinoma Gl... 展开 >>ucagonoma Insulinoma Metastatic Gastrointestinal Carcinoid Tumor Pancreatic Polypeptide Tumor Pulmonary Carcinoid Tumor Recurrent Gastrointestinal Carcinoid Tumor Recurrent Islet Cell Carcinoma Somatostatinoma 收起 <<	Phase 2	Recruiting	August 16, 2020	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Not yet recruiting Scottsdale, Arizona, United States, 85259 Contact: Thorvardur R. Halfdanarson 507-538-7623 Halfdanarson.Thorvardur@mayo.edu Principal Investigator: Thorvardur R. Halfdanarson United States, California USC Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Dana Agafitei 323-865-0467 Raluca.Agafitei@med.usc.edu Principal Investigator: Syma Iqbal Hoag Memorial Hospital Presbyterian Recruiting Newport Beach, California, United States, 92663 Contact: Alicia Bogardus, MA 949-764-6755 Alicia.bogardus@hoag.org Principal Investigator: Diana Hanna, MD USC Norris Oncology Hematology‐Newport Beach Recruiting Newport Beach, California, United States, 92663 Contact: Kristy Massopust 949-474-5733 Kristy.Massopust@med.usc.edu Principal Investigator: Greg Angstreich, MD United States, Washington Seattle Cancer Care Alliance Not yet recruiting Seattle, Washington, United States, 98109 Contact: William P. Harris 206-688-7175 wph3@u.washington.edu Principal Investigator: William P. Harris 收起 <<
NCT03010722	-		Recruiting	July 2017	United Kingdom ... 展开 >> The Royal Marsden NHS Foundation Trust London and Surrey Recruiting Carshalton, Surrey, United Kingdom, SM2 5PT Contact: Claire Saffery 02086613637 claire.saffery@rmh.nhs.uk Contact: Dr Khurum Khan 02086426011 ext 1123 khurum.khan@rmh.nhs.uk 收起 <<
NCT02466009	Metastatic Colorectal Cancer	Phase 2	Recruiting	July 2019	United States, Minnesota ... 展开 >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55901 Contact: Joleen M Hubbard, M.D. 507-284-8318 Hubbard.Joleen@mayo.edu Sub-Investigator: Joleen Hubbard, MD United States, New York University of Rochester Recruiting Rochester, New York, United States, 14642 Principal Investigator: Mohamed Tejani, MD Sub-Investigator: Supriya Mohile, MD United States, North Carolina University of North Carolina at Chapel Hill Recruiting Chapel Hill, North Carolina, United States, 27514 Contact: Grant R Williams, MD 919-966-0000 Grant.Williams@unchealth.unc.edu United States, Pennsylvania Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Principal Investigator: Efrat Dotan, MD 收起 <<
NCT02606097	Gastrointestinal Stromal Tumou... 展开 >>r (GIST) 收起 <<	Phase 2	Unknown	-	Taiwan ... 展开 >> Chang Gung Memorial Hospital Recruiting Taoyuan, Taiwan, 333 Contact: Chun-Nan Yeh, MD 886-3-3281200 ext 3219 yehchunnan@gmail.com 收起 <<
NCT01996969	Metastatic Colorectal Cancer	Not Applicable	Unknown	May 2016	Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 收起 <<
NCT03627728	Gastric Cancer	Phase 2	Recruiting	December 2021	Italy ... 展开 >> Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova Recruiting Reggio Emilia, Italy, 42123 Contact: gnoni roberta, biologist +390522295181 gnoni.roberta@ausl.re.it 收起 <<
NCT02116894	Colorectal Cancer	Phase 1	Completed	-	United States, North Carolina ... 展开 >> Duke Cancer Center, Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT02465502	Colorectal Neoplasms	Phase 2	Completed	-	Brazil ... 展开 >> São Paulo, Brazil, 01246000 收起 <<
NCT02459119	Urothelial Cancer (Urinary Bla... 展开 >>dder, Ureters, or Renal Pelvis Cancer) 收起 <<	Phase 2	Recruiting	December 2019	United States, Alabama ... 展开 >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35294 Contact: Pam Dixon, RN, BSN, OCN 205-975-5387 pamdixon@uab.edu Principal Investigator: Lisle Nabell, MD United States, Michigan Wayne State University Recruiting Detroit, Michigan, United States, 48201-2013 Contact: Ulka N Vaishampayan, MD 313-576-8715 vaishamu@karmanos.org United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Petros Grivase, MD, PhD 216-636-0100 grivasp@ccf.org 收起 <<
NCT02095054	Advanced Cancers	Phase 1	Active, not recruiting	March 2023	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02664077	Stage III (IIIB or IIIC) Colon... 展开 >> Cancer 收起 <<	Phase 3	Active, not recruiting	October 2019	-
NCT01933958	-		Recruiting	January 30, 2021	Japan ... 展开 >> Recruiting Multiple Locations, Japan 收起 <<
NCT02425683	Colorectal Neoplasms ... 展开 >> Adenocarcinoma of the Colon Adenocarcinoma of the Rectum 收起 <<	Phase 2	Terminated(insufficient accrua... 展开 >>l) 收起 <<	-	United States, Florida ... 展开 >> 24 Sites Including Dallas, TX, Ocala, FL, Denver, CO, Florida, United States 收起 <<
NCT02115542	Cancer of the Bile Duct	Phase 2	Active, not recruiting	October 2020	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27514 United States, Virginia VCU Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT02581059	Colorectal Cancer ... 展开 >> Palliative Medicine Supportive Care 收起 <<	Phase 2	Terminated(Funder terminated.)	-	United States, Indiana ... 展开 >> Indiana Univeristy Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 IU Health Central Indiana Cancer Centers Indianapolis, Indiana, United States, 46219 United States, New Jersey Altantic Health System Morristown, New Jersey, United States, 07960 United States, North Carolina Comprehensive Cancer Center at Wake Forest Baptist Winston-Salem, North Carolina, United States, 27157 United States, Pennsylvania Gettysburg Cancer Center Gettysburg, Pennsylvania, United States, 17325 收起 <<
NCT02402036	Colon Cancer	Phase 2	Terminated	-	United States, District of Col... 展开 >>umbia Georgetown University Washington, District of Columbia, United States, 20007 收起 <<
NCT02736305	Ovarian Neoplasms	Phase 2	Recruiting	June 2019	Singapore ... 展开 >> National Cancer Centre Singapore Recruiting Singapore, Singapore, 169610 收起 <<
NCT02657551	Thyroid Cancer	Phase 2	Recruiting	October 2022	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Jochen Lorch, MD 617-632-3090 jlorch@partners.org Principal Investigator: Jochen Lorch, MD 收起 <<
NCT03712943	Colorectal Cancer ... 展开 >> Metastatic Colorectal Cancer Colon Cancer 收起 <<	Phase 1	Recruiting	October 2022	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Taymeyah E Al-Toubah 813-745-6454 Taymeyah.Al-Toubah@moffitt.org Principal Investigator: Dae W Kim, MD Sub-Investigator: Richard Kim, MD 收起 <<
NCT02175095	Colorectal Cancer	Not Applicable	Active, not recruiting	April 2018	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Songpa, Korea, Republic of, 138736 收起 <<
NCT01929616	Advanced Chemorefractory Color... 展开 >>ectal Adenocarcinoma 收起 <<	Phase 2	Active, not recruiting	May 2017	Belgium ... 展开 >> UZA Antwerpen, Edegem, Belgium, 2650 Jules Bordet Institute Brussels, Belgium, 1000 Hopital Erasme Brussels, Belgium, 1070 Cliniques Universitaires Saint Luc Brussels, Belgium Grand Hopital de Charleroi Charleroi, Belgium, 6000 UZ Ghent Ghent, Belgium AZ groeninge Kortrijk, Belgium, 8500 Centre Hospitalier Universitaire de Liège Liège, Belgium, 4000 Clinique St Joseph Liège, Belgium, 4000 Centre hospitalier de Jolimont Lobbes, Belgium, 6540 CHU Ambroise Paré Mons, Belgium, 7000 Centre Hospitalier Régional de Namur Namur, Belgium, 5000 Clinique et Maternité Sainte Elisabeth Namur, Belgium, 5000 Clinique Saint Pierre Ottignies, Belgium, 1340 Hartziekenhuis Roeselare-Menen (HHRM) Roeselare, Belgium, 8800 AZ Turnhout Turnhout, Belgium, 2300 Cliniques Universitaires UCL de Mont-Godinne Yvoir, Belgium, 5530 收起 <<
NCT03406871	Advanced and Metastatic Solid ... 展开 >>Tumor 收起 <<	Phase 1 Phase 2	Recruiting	July 31, 2022	Japan ... 展开 >> NationalCCHE Recruiting Kashiwa, Chiba, Japan, 277-8577 Contact: Kohei Shitara, Dr +81-4-7133-1111 ext 91520 kshitara@east.ncc.go.jp Contact: Shota Fukuoka, DR +81-4-7133-1111 ext 91283 shfukuok@east.ncc.go.jp 收起 <<
NCT01949194	Metastatic Colorectal Cancer	Phase 2	Active, not recruiting	December 2018	Canada, New Brunswick ... 展开 >> The Moncton Hospital (Horizon Health Network) Moncton, New Brunswick, Canada, E1C 6Z8 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 St-Mary's Hospital Centre Montreal, Quebec, Canada, H3T 1M5 McGill University Health Centre Montréal, Quebec, Canada, H4A 3J1 Canada Hopital Maisonneuve-Rosemont Montreal, Canada, H1T 2M4 收起 <<
NCT02466802	Solid Tumor	Phase 1	Active, not recruiting	June 30, 2020	United States, Virginia ... 展开 >> Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT02307500	Pancreas Cancer ... 展开 >> Ovarian Cancer Melanoma Sarcoma 收起 <<	Phase 2	Recruiting	January 2019	Italy ... 展开 >> Istituto Clinico Humanitas Recruiting Rozzano, Milan, Italy, 20089 收起 <<
NCT03722108	Adenocarcinoma of the Stomach ... 展开 >> Adenocarcinoma of the Gastroesophageal Junction 收起 <<	Phase 1 Phase 2	Not yet recruiting	November 2023	France ... 展开 >> Institut du Cancer Montpellier Not yet recruiting Montpellier, France, 34298 Contact: Emmanuelle MD SAMALIN-SCALZI, PhD 33 (0)467612592 emmanuelle@samalin@icm.unicancer.fr 收起 <<
NCT02651415	Metastatic Colorectal Cancer	Phase 2	Active, not recruiting	August 2018	Canada, British Columbia ... 展开 >> BC Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 收起 <<
NCT03042689	Acute Myeloid Leukemia	Phase 1	Recruiting	January 2023	United States, Massachusetts ... 展开 >> Massachusetts general Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Gabriela Hobbs, MD 617-724-1124 Principal Investigator: Gabriela Hobbs, MD 收起 <<
NCT02439723	Metastatic Solid Malignancies ... 展开 >> Locally Advanced Solid Malignancies 收起 <<	Phase 1	Unknown	December 2017	Canada, Alberta ... 展开 >> Cross Cancer Institute Not yet recruiting Edmonton, Alberta, Canada, T6G 1Z2 Contact: Michael Sawyer, MD 780-432-8248 收起 <<

CAS号	755037-03-7
分子式	C₂₁H₁₅ClF₄N₄O₃
分子量	482.82
SMILES Code	O=C(NC)C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C(F)=C2)=C1
MDL No.	MFCD16038047

别名	瑞格非尼 ;BAY 73-4506; Fluoro-Sorafenib
运输	蓝冰
InChI Key	FNHKPVJBJVTLMP-UHFFFAOYSA-N
Pubchem ID	11167602

DLD1	1-20 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose-dependent manner	25071018
DLD1	1-10 μM	Apoptosis Assay	48 h	induces cell death in a dose-dependent manner	25071018
DLD1	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
GBM12	0.5–1.0 μM	Apoptosis Assay	24 h	interacts with lapatinib to induce cell death	24911215
GBM14	0.5–1.0 μM	Apoptosis Assay	24 h	interacts with lapatinib to induce cell death	24911215
GBM5	0.5–1.0 μM	Apoptosis Assay	24 h	interacts with lapatinib to induce cell death	24911215
GBM6	0.5–1.0 μM	Apoptosis Assay	24 h	interacts with lapatinib to induce cell death	24911215
GEO	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
GEO-CR	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
HCT116	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
HCT116	10/20/40 μM	Function Assay	24 h	induces PUMA protein and mRNA expression in a dose- and time-dependent manner	24763611
Hct-116	1-20 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose-dependent manner	25071018
Hct-116	1-10 μM	Apoptosis Assay	48 h	induces cell death in a dose-dependent manner	25071018
HCT150	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
HEK293	0.5 μM	Function Assay	2/4/6 h	reduces GRP78 expression	25858032
HEK293		Growth Inhibition Assay		IC50=11.0±1.2 nM	25753361
HEK293/OATP1B1		Growth Inhibition Assay		IC50=6.2±0.3 nM	25753361
Hep3B	1–5 μM	Apoptosis Assay	48 h	inhibits cell growth	26329608
Hep3B	1–2.5 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth	24885890
Hep3B	1–5µM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth	23169148
HepG2	1–5 μM	Apoptosis Assay	48 h	inhibits cell growth	26329608
HepG2	1–2.5 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth	24885890
HepG2	1–5µM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth	23169148
HROC18		Growth Inhibition Assay		IC50=1.3 μM	25309914
HROC24		Growth Inhibition Assay		IC50=4.6 μM	25309914
HROC43		Growth Inhibition Assay		IC50=5.3 μM	25309914
HROC46		Growth Inhibition Assay		IC50=2.4 μM	25309914
HT15	1-20 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose-dependent manner	25071018
HT15	1-10 μM	Apoptosis Assay	48 h	induces cell death in a dose-dependent manner	25071018
HT29	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
HT29	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
HT-29	1-20 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose-dependent manner	25071018
HT-29	1-10 μM	Apoptosis Assay	48 h	induces cell death in a dose-dependent manner	25071018
KB-31		Growth Inhibition Assay		IC50=5.5±0.3 nM	25753361
KB-G2		Growth Inhibition Assay		IC50=9.1±0.1 nM	25753361
Lim1215	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
Lim2405	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
LLC-PK1		Growth Inhibition Assay		IC50=42.0±3.2 nM	25753361
LLC-PK1/MRP2		Growth Inhibition Assay		IC50=82.4±2.7 nM	25753361
LOVO	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
LoVo	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
MCF-7	0.5/5 μM	Function Assay	24 h	inhibits the cell migration	25253994
MDA-MB-231	0.5/5 μM	Function Assay	24 h	inhibits the cell migration	25253994
PLC/PRF/5	1–5 μM	Apoptosis Assay	48 h	inhibits cell growth	26329608
PLC/PRF/5	1–2.5 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth	24885890
PLC/PRF/5	1–5µM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth	23169148
RJ345	0.5/5 μM	Function Assay	24 h	inhibits the cell migration	25253994
RJ348	0.5/5 μM	Function Assay	24 h	inhibits the cell migration	25253994
RKO	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
SW1463	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
SW48	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
SW48	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
SW480	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
SW480	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
SW48-CR	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
SW620	0.01-20 μM	Growth Inhibition Assay	96 h	inhibits cell growth in a dose-dependent manner	25838391
SW837	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
Vaco400	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611
Vaco432	40 μM	Function Assay	24 h	induces PUMA protein and cell apoptosis	24763611

Regorafenib/瑞戈非尼 {[allProObj[0].p_purity_real_show]}

Regorafenib/瑞戈非尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Regorafenib/瑞戈非尼质控信息

Regorafenib/瑞戈非尼生物活性

Regorafenib/瑞戈非尼细胞实验

Regorafenib/瑞戈非尼动物实验

Regorafenib/瑞戈非尼临床研究

Regorafenib/瑞戈非尼实验方案

Regorafenib/瑞戈非尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR1	VEGFR1, IC50:13 nM
VEGFR3	VEGFR3, IC50:46 nM
VEGFR2	VEGFR2, IC50:4.2 nM
c-RET	RET, IC50:1.5 nM

Regorafenib/瑞戈非尼 {[allProObj[0].p_purity_real_show]}

Regorafenib/瑞戈非尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Regorafenib/瑞戈非尼 质控信息

Regorafenib/瑞戈非尼 生物活性

Regorafenib/瑞戈非尼 细胞实验

Regorafenib/瑞戈非尼 动物实验

Regorafenib/瑞戈非尼 临床研究

Regorafenib/瑞戈非尼 实验方案

Regorafenib/瑞戈非尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Regorafenib/瑞戈非尼纯度/质量文件产品仅供科研

Regorafenib/瑞戈非尼质控信息

Regorafenib/瑞戈非尼生物活性

Regorafenib/瑞戈非尼细胞实验

Regorafenib/瑞戈非尼动物实验

Regorafenib/瑞戈非尼临床研究

Regorafenib/瑞戈非尼实验方案

Regorafenib/瑞戈非尼技术信息